Today in Medicine: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Medicine.

Press releases published on July 7, 2026

Jul. 7, 2026

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

Indeterminate GlobeNewswire

Jul. 7, 2026

Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential

Indeterminate GlobeNewswire

Jul. 7, 2026

Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy

Indeterminate GlobeNewswire

Jul. 7, 2026

Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results

Indeterminate GlobeNewswire

Jul. 7, 2026

HMNC Brain Health Announces Publication of Ketabon (KET01) Clinical Trial Results in JAMA Network Open

Indeterminate GlobeNewswire

Jul. 7, 2026

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026

Indeterminate GlobeNewswire

Jul. 7, 2026

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

Indeterminate GlobeNewswire

Jul. 7, 2026

Endogenex Announces Full Enrollment of the ReCET Clinical Study

Indeterminate GlobeNewswire

Jul. 7, 2026

MariMed’s Nature’s Heritage Launches “The Nose Knows” Immersive, Science-Backed Consumer Education Campaign

Indeterminate GlobeNewswire

Jul. 7, 2026

Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

Indeterminate GlobeNewswire

Jul. 7, 2026

Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum

Indeterminate GlobeNewswire

Jul. 7, 2026

Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader

Indeterminate GlobeNewswire

Jul. 7, 2026

Aclarion Announces Texas Spine Care Center as New CLARITY Site

Indeterminate GlobeNewswire

Jul. 7, 2026

ImageneBio Appoints Matt Robbins as General Counsel

Indeterminate GlobeNewswire

Jul. 7, 2026

U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease

Indeterminate GlobeNewswire

Jul. 7, 2026

Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

Indeterminate GlobeNewswire

Jul. 7, 2026

Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease

Indeterminate GlobeNewswire

Jul. 7, 2026

OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium

Indeterminate GlobeNewswire

Jul. 7, 2026

Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535

Indeterminate GlobeNewswire

Jul. 7, 2026

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP

Indeterminate GlobeNewswire